USAEUROPEViVE
ABOUTSPONSORSHIPFOUNDATION
Logo Hlth
Logo Hlth
23 Jun 2022 | 02:45 PM GMT

The DTx opportunity for Pharma Companies

Anchored by:

Omri Shor
CEO
MEDISAFE
Chris Cera
CEO
ARCWEB TECHNOLOGIES

Participants:

Chris Cera CEOArcweb Technologies
Chris Cera
CEOArcweb Technologies
Omri Shor CEOMedisafe
Omri Shor
CEOMedisafe
Alyssa Dietz Vice President, Clinical StrategyTwill (formerly Happify Health)
Alyssa Dietz
Vice President, Clinical StrategyTwill (formerly Happify Health)
Arnaud Muller CX Excellence & Planning LeaderDaiichi Sankyo
Arnaud Muller
CX Excellence & Planning LeaderDaiichi Sankyo
Brian Mahony Medical Research FellowBioinnovate
Brian Mahony
Medical Research FellowBioinnovate
Cathy Zaremba Director, Product MarketingBrightInsight
Cathy Zaremba
Director, Product MarketingBrightInsight
Nayan Kalnad CEOAvegen Health
Nayan Kalnad
CEOAvegen Health
Vishal Sahni Director, Corporate Business Dev. & StrategyLundbeck
Vishal Sahni
Director, Corporate Business Dev. & StrategyLundbeck

About this Meeting

While the relationship between digital therapeutics (DTx) and pharma is still in its infancy, we are seeing the emergence of some compelling models and partnerships that illustrate the opportunities in the market. However, the failure rate within partnerships is high and it seems that we are yet to find a solution for the culture clash between pharma and DTx. What opportunities are proving the best strategic fit for pharma and how can companies successfully commercialize the undoubted potential to ease some patient pain points?  

At this meeting, we will dive into the different approaches for pharma, both for revenue-generating DTx and other models to create value such as cost-saving, patient adherence and patient data for R&D purposes. Join us in this informal conversation with leaders of the industry where we will speak on topics such as:  

  • How can pharma incorporate DTx into the traditional business model? What internal issues need to be navigated?  
  • What opportunities are pharma companies capitalizing on and what opportunities have yet to be realized? 
  • How can pharma successfully build partnerships with other DTx companies? At what stage should a partnership begin and what proof points are required?   
  • How does buying vs. building fit into the strategy? Does it make sense to buy in the short-term and build out teams skill sets in the long-term? How can pharma harness internal innovation from their own staff and marry that to external partnership opportunities?